The Longevity Fund

Longevity Fund is a venture capital firm that focuses on extending healthy human lifespan through medical innovations. Established in 2013, the firm is dedicated to investing in biotech startups developing therapies to combat age-related diseases. The fund primarily supports early-stage companies, especially those pioneering treatments aimed at slowing or reversing the aging process. The firm has backed several significant players in the longevity field, including Unity Biotechnology, Spring Discovery, and Loyal. These companies are working on groundbreaking solutions in areas such as cellular senescence, AI-driven drug discovery, and tissue regeneration. The Longevity Fund also collaborates with age1, an accelerator designed to support founders working in this niche sector. Longevity Fund’s investment strategy is built around founder-led companies with a mission-driven approach. They believe the next generation of biotech leaders will be those who are passionate about fundamentally transforming medicine to extend life expectancy. The firm seeks startups that are not only scientifically innovative but also have a clear path toward FDA approvals and scalable business models. Based in San Francisco, Longevity Fund continues to push the boundaries of what is possible in healthcare, aiming to make age-related diseases a thing of the past and give individuals more control over the number of healthy years they can live.